Research Article
Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations
Table 1
Correlation between membrane composition and pharmacokinetics parameters of cisplatin-containing liposomes.
| | Formulation | % DS | % DP | T m (°C) | Cisplatin T 1/2 (h) | AUMC cisplatin (mg·h2/mL) | Lipid T 1/2 (h) | AUMC lipid (mg·h2/mL) |
| | DSPC : CHOL (55 : 45) | 55 | 0 | 55.3 | 18.9 | 82.6 | 23.5 | 12894.5 | | DSPC : DSPG : Chol (7 : 2 : 1) | 90 | 0 | 54.9 | 14.7 | 27.8 | 28.0 | 9892.3 | | DSPC : DPPC : DSPG : Chol (6 : 1 : 2 : 1) | 80 | 10 | 52.5 | 11.6 | 22.1 | 29.3 | 11836.8 | | DSPC : DPPC : DSPG : Chol (35 : 35 : 20 : 10) | 55 | 35 | 48.8 | 8.3 | 6.6 | 15.3 | 2953.0 | | DSPC : DPPC : DPPG : Chol (35 : 35 : 20 : 10) | 35 | 55 | 45.5 | 6.8 | 4.8 | 16.6 | 3511.0 | | DPPC : DPPG : Chol (7 : 2 : 1) | 0 | 90 | 42.2 | 4.5 | 1.7 | 9.3 | 1058.9 |
|
|
The T 1/2 and AUMC values presented in this table were based on plasma measurements recorded within the first 24 hours of administration.
|
